Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3Thoracic 2Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Sarcoma 3Neoplasm Metastasis 3Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Carcinoid Tumor 1

Interventions

pembrolizumab 11Gemcitabine 10Doxorubicin 10Cyclophosphamide 9Specimen Handling 8Nivolumab 8Ibandronic Acid 8pazopanib 7Radiosurgery 6Magnetic Resonance Spectroscopy 6Imatinib Mesylate 6Biopsy 6Bevacizumab 6Irinotecan 5regorafenib 4Zoledronic Acid 4Ipilimumab 4Ifosfamide 4Fluorouracil 4Docetaxel 4Cetuximab 4sargramostim 3conatumumab 3cemiplimab 3Sunitinib 3Radiation 3Paclitaxel 3Leucovorin 3Cryosurgery 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasm Metastasis × conatumumab × Sarcoma × Clear all
NCT00819169 2024-08-20

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

NantCell, Inc.

Phase 1/2 Terminated
89 enrolled 20 charts
GastrointestinalGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed
12 enrolled 21 charts
EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT00626704 2015-05-25

Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

Amgen

Phase 1/2 Completed
134 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡